

TABLE 1  
The Distribution of Sex and Age of 100 Patients with A.L.E.

AGE	F	M	TOTAL
1-	2	3	5
11-	1		1
21-	3	5	8
31-	10	2	12
41-	16	7	23
51-	21	7	23
61-	20	1	21
71-	2		2
<u>TOTAL</u>	<u>75</u>	<u>25</u>	<u>100</u>

TABLE 2

## ALF Dosage

	Patient		Dosage (cc/qdd) (minimum dose in cc that triggers blastogenesis)	
	No.	%	Range	Mean
Normal	47	47	0.1	0.1
Build up	37	37	0.15-1.0	0.3
Dilution	16	16	0.01- 0.00001	0.05

TABLE 3  
The Distribution of Time of Therapy

Months	2	3	4	5	6	7	8	9	10	11	>12
No. Patients	8	14	11	7	7	6	10	6	4	7	20

Average therapy time:  $7.4 \pm 3.8$  months

Range: 2-16 months

TABLE 4

## The Distribution of Dosage of Therapy

Dosage (cc)	2	3	4	5	6	7	8	9	10	11	>12
No. Patients	8	13	15	6	8	11	10	6	4	7	14

Average therapy       $6.44 \pm 3.79$  cc

Range: 2-25 cc

TABLE 5

Scale of Clinical Symptoms and Signs of  
The Patient After ALF Treatment  
(Severity)

Symptoms	Improvement		No Change		Worsening		Total Patients
	No.	%	No.	%	No.	%	
Hypersensitive Reaction	63	63	33	33	1	1	100
Recurrent Infection	38	57	29	43	0	0	67
Fatigue	60	68	27	31	1	1	88
Lack of Concentration	43	54	36	46	0	0	79
Arthritis	19	44	23	54	1	2	43
G.I. Upset	29	40	43	60	0	0	72
Headache	28	44	33	53	2	3	64
Depression	42	58	30	42	0	0	72

TABLE 6  
Scale of Clinical Symptoms and Signs of  
The Patient After ALF Treatment  
(Frequency)

Symptoms	Improvement		No Change		Worsening		Total Patients
	No.	%	No.	%	No.	%	
Hypersensitive Reaction	38	38	62	62	0	0	100
Recurrent Infection	26	39	41	61	0	0	67
Fatigue	38	43	50	57	0	0	88
Lack of Concentration	20	25	59	75	0	0	79
Arthritis	11	26	32	74	0	0	43
G.I. Upset	21	29	51	69	0	0	72
Headache	19	30	45	70	0	0	64
Depression	30	42	42	58	0	0	72

TABLE 7  
The Changes of T&B Profile of 92 Patients Treated with ALF

	TOTAL LYMPHOCYTES	T <sub>H</sub>	T <sub>4</sub>	T <sub>8</sub>	T <sub>4</sub> /T <sub>8</sub>	B <sub>4</sub>
BEFORE	2112±632	1624±457	930±45	439±58	2.3±0.8	188±102
AFTER	2232±678 *	1634±544	1027±297 **	478±189 **	1.3±.4	171±120

n = 92

\* p&lt;0.05

\*\* p&lt;0.01

TABLE 8

T Lymphocyte Subsets of 92 Patients After AIF Treatment

	TOTAL LYMPHOCYTES		T <sub>h</sub>		T <sub>i</sub>		T <sub>s</sub>	
	NO.	%	NO.	%	NO.	%	NO.	%
INCREASE	52	57	41	46	53	58	55	60
DECREASE	40	43	51	54	39	42	37	40
P	<0.05		>0.05		<0.05		<0.01	



TABLE 9  
CMI Results with ALF Effect  
CMI Scores (Number and Size,  $\bar{x} \pm SD$ )

NO. PATIENTS	BEFORE ALF	AFTER ALF	P
78	5.46 $\pm$ 5.81	9.28 $\pm$ 7.25	<0.001

CMI Positive Score  
(Number and Size) After ALF

	NO. PATIENTS	%	P
INCREASE	58	74	<0.001
NO CHANGE	9	12	
DECREASE	11	14	

The Relationship Between CMI and Clinical Symptom and Sign Improvement

	IMPROVEMENT NO.	%	NO IMPROVEMENT NO.	%	P
CMI INCREASE	56	72	2	3	<0.001
CMI NO CHANGE & DECREASE	14	18	6	8	

TABLE 10

## Side Effects of ALF - (5% of Patients Can Not Tolerate ALF)

1. PAIN AND IRRITATION IN THROAT, BURNING IN THE EYES
2. NAUSEA
3. CHEST TIGHTNESS AND HEART PALPITATION
4. FLU-LIKE SYMPTOMS, HEADACHE, FATIGUE, CHILL
5. INCREASE IN FOOD AND ODOR SENSITIVITY

TABLE 11

**190 Patients with ALF**

	No.	%
Female	131	69
Male	59	31
Age:	2-76 years old	
Mean:	46.8 years old	

TABLE 12

## ALF Dosage

Patient		Dosage (cc/q4d) (minimum dose in cc that triggers blastogenesis)	
No.	%	Range	
Normal	88	46	0.1 (1:10)
Build up	84	44	0.15-1.0 (1:10)
Dilution	18	9	0.1 (1:20, 1:10 <sup>2</sup> -1:10 <sup>6</sup> )

TABLE 13  
The distribution of period of ALF therapy

Month	No. Patients	%
1-3	27	14.2
4-6	19	10.0
7-9	25	13.2
10-12	20	10.5
13-15	11	5.8
16-18	21	11.1
19-21	21	11.1
22-24	7	3.7
24-26	14	7.4
27-29	11	5.8
30-32	5	2.6
33-36	9	4.7
Average: 14.6 months (Range 1-37 months)		

TABLE 14

## The Distribution of dosage of ALF

Dosage (cc)	No. Patient	%
1-5	45	23.7
6-10	59	31.1
11-20	66	34.7
21-30	19	10
31-40	1	0.5
Total	190	100

Average: 11.27 (cc)

Range: 1-38 (cc)

TABLE 15

Scale of Clinical Symptoms and Signs of The C.S. Patient After  
ALF Treatment (Severity)

Symptoms	Improvement No. %	No Changes No. %	Worsening No. %	Total Patients
Hypersensitive				
Reaction	51 56.7	33 36.7	6 6.7	90
Recurrent				
Infection	33 50.8	27 41.5	5 7.7	65
Fatigue	58 71.6	17 20.99	6 7.4	81
Lack of				
Concentration	42 57.5	29 39.7	2 2.7	73
Arthritis	20 44.4	22 48.9	3 6.7	45
G.I Upset	32 44.4	33 45.8	7 9.7	72
Headache	30 40.5	38 51.4	6 8.1	74
Depression	44 63.8	22 31.9	3 4.3	69

TABLE 16  
 Scale of Clinical Symptoms and Signs of The Patient After  
 ALF Treatment (frequency)

Symptoms	Improvement No. %	No Changes No. %	Worsening No. %	Total Patients
Hypersensitive				
Reaction	28 36.4	46 59.7	3 3.9	77
Recurrent				
Infection	27 46.6	27 46.6	4 6.9	58
Fatigue	36 47.4	37 48.7	3 3.9	76
Lack of				
Concentration	23 33.8	43 63.2	2 2.9	68
Arthritis	13 32.5	24 60.0	3 7.5	40
G.I. Upset	23 37.1	35 56.5	4 6.5	62
Headache	24 38.1	34 54.0	5 7.9	63
Depression	34 54.8	26 41.9	2 3.2	62



TABLE 17  
T&B Lymphocytes Parameters Changes After ALF

	(N)	Before (mean±SE)	After
WBC	25	4180±404.1**	4828±1164.6
Lymphs	34	1350 ±225.1**	1573.2±448.2
T11	32	989.4±198.1**	1182.6±331.2
T4	30	518.2±107.2**	689.5 ±200.1
Ratio of T4/T8	46	3.62± 0.99**	2.71± 1.04
T8	52	248.6±63.3**	354.3 ±124.9
B4	35	54.8±17.0**	121.3±78.7

\*\*-P<0.01 (Change compared with before ALF therapy )

TABLE 18  
T&B Lymphocytes parameters improvement after  
ALF

	Patients No.	Improved No.	(%)
WBC	25	18	72%
Lymphs	34	25	74%
TII	32	21	66%
T4	30	24	80%
Ratio of T4/T8	46	37	80.4%
T8	52	40	76.9%
B4	35	27	77%

TABLE 19  
CMI Improvements of 93 Patients with ALF

	<u>Total No. of Antigen Responses</u>
Increase	247*
Decrease	171
<u>No change</u>	<u>233</u>
Total	651

\* P<0.001 compared with decrease

TABLE 20

**Diagnosis**

	<u>No.</u>	<u>%</u>
Chemical sensitivity	127	67
Food Sensitivity	106	56
Inhalant Sensitivity	84	44
EMF Sensitivity	9	5

TABLE 21

## Diagnosis

	No.	%
N.S	104	54.7
C.V	53	27.9
G.I	59	31.1
G.U	15	7.9
M.S	107	56.3
EYE	4	2.1
Respiratory	87	45.8
Skin	22	11.6
Endocrine	24	12.6
Immune		
dysregulation	99	52.1
Chronic		
infection	42	22.1
Implant	7	3.7
Parasite	3	1.6
Carcinoma	3	1.6
Candidosis	8	4.2
HIV positive	1	0.5

TABLE 22

50 Year Old White Female  
HIV Positive

0.1cc every 4 doses		
CMI before -1	CMI after 3	
WBC - 3,500	10,000	
T <sub>0</sub> 964	1359	
T <sub>0</sub> * 54	73%	
T <sub>4</sub> 149	750	
T <sub>4</sub> * 3%	40%	
T <sub>8</sub> 464	875	
T <sub>8</sub> * 26	47%	
T <sub>4</sub> /T <sub>8</sub> .17	1.62	
B 36	93	
B% 2	5%	
Sx-fatigue, neuropathy	Energy	
Stomach Pain	- gone	
Non healing toe	- gone	
Lesion for 2 yrs.	- gone	
Took ALP for 5 months, then stopped		
All Sx exacerbated for 3 weeks.		
Restarted ALP and Sx disappeared		

TABLE 23

B: Before ALF  
A: After ALF

PATIENTS WITH CANCER & ALF

	46 Y F Breast Cancer	59 Y F Breast Cancer	84 Y F Leukemia	67 Y F para- thyroid tumor	42 Y F Breast Cancer	63 Y F Left Breast Nastectomy	23 Y M Osteo- genic Sarcoma
	3/1/95 9/3/96	6/1/95 7/21/95	10/20/94 2/7/95	3/25/96 1/9/97	10/10/94 5/30/95	10/31/96 1/10/97	4/8/96 9/24/96
	0.1cc 0.2cc 90 doses	0.1cc	0.1cc	1:10 <sup>3</sup> -1:10 0.1cc	0.1cc	0.1cc	0.1cc
	B A	B A	B A	B A	B A	B A	B A
Tetanus	3	0	0	30	5	0	5
Diphtheria	4	0	0	6	4	0	0
Streptococcus	0	0	0	0	0	0	0
Tuberculin	0	0	0	0	0	0	0
Control	0	0	0	0	0	0	0
Candida	0	0	0	0	0	0	0
Trichophyton	0	0	0	0	0	0	0
Proteus	0	4	0	0	4	0	0

TABLE 23 (CONTINUED)

	46 Y F Breast Cancer	59 Y F Breast Cancer	84 Y F Leuk- emia	67 Y F Para- thyroid tumor	62 Y F Breast Cancer	61 Y F Left Breast	23 Y M Osteo- sarcoma
NBC	B A	B A	B A	B A	B A	B A	B A
	6900 43004 5100 47004		223004	7090	4700 4500	5300 6760	
Lymphocytes	3277 7220 1848		153871	2590	1833 1305	2412	1431
1g	33 50 44		69	37	39 29	36	27
T <sub>H</sub>	1867 10564 1734 1478		49231	1968	1448 861	1787	1188
T <sub>H</sub>	82 62 68 80		32	76	79 56	72	83
T <sub>L</sub>	1002 3784 944 812		23081	1606	733 469	724	587
T <sub>A</sub>	44 37 231 45		154	621	40 36	30	41
T <sub>L</sub>	433 482 612 591		26167	544	495 235	599	329
T <sub>A</sub>	19 26 34 32		17	21	27 18	29	23



